Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the FGlobeNewsWire • 02/27/24
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3GlobeNewsWire • 02/27/24
Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 EarningsZacks Investment Research • 02/26/24
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024GlobeNewsWire • 02/21/24
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women's HealthGlobeNewsWire • 02/15/24
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision GenomicsGlobeNewsWire • 02/01/24
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of OncologyGlobeNewsWire • 01/30/24
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision GenomicsGlobeNewsWire • 01/18/24
Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSOGlobeNewsWire • 01/09/24
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial GuidanceGlobeNewsWire • 12/21/23
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient CareGlobeNewsWire • 12/20/23
Kiyatec strengthens its leadership position with the addition of Mark Capone, former CEO of Myriad Genetics, as Strategic AdvisorBusiness Wire • 11/21/23
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant ParentsGlobeNewsWire • 11/20/23
Myriad Genetics and Personalis Partner to Market Solutions to Pharma CustomersGlobeNewsWire • 11/16/23